MyChesCo on MSN3d
Optinose Reports 2024 Financial Results, Highlights Prescription Growth and First Operational Income
Optinose (NASDAQ: OPTN) has announced its financial results for the year and quarter ending December 31, 2024, spotlighting ...
Optinose, Inc.: Optinose Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Operational Highlights
Company reports fourth quarter and full year 2024 XHANCE net revenue of $22.4 million and $78.2 million, increases of 13% and 10% compared to prior year periods Company reports 23% prescription growth ...
Zacks Investment Research on MSN5d
Biotech Stock Roundup: SAVA Dives on Setback, ALNY Up on Update & More
It was a busy week in the biotech sector with important regulatory and pipeline updates. Among these, Cassava Sciences, Inc ...
OptiNose (OPTN) Reports Q4 Loss, Tops Revenue Estimates
OptiNose (OPTN) delivered earnings and revenue surprises of 95.71% and 5.57%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Optinose Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Operational Highlights
Company reports fourth quarter and full year 2024 XHANCE net revenue of $22.4 million and $78.2 million, increases of 13% and 10% compared to ...
OptiNose: Q4 Earnings Snapshot
OptiNose Inc. OPTN) on Wednesday reported a loss of $360,000 in its fourth quarter.
Optinose reports Q4 EPS (3c) vs ($1.33) last year
Reports Q4 revenue $22.418M, consensus $20.82M.Light Up your Portfolio with Spark:Easily identify stocks' risks and opportunities. Discover ...